I am a little torn about the trading yesterday. On the one hand, it looks like a washout low with a reversal, which is really good. On the other hand, if we cannot continue that momentum and move significantly higher that might only be a small respite for another move lower later this month. Remember […]
January 13th Biotech Update
JPM week starts with some deals, some potential deals, data, pre-announcements and most importantly I think a disappointed investor sentiment. I think there is enough to not be a true bust for the sector, but I also do not think there is enough action to really generate enough interest in the sector. It is still […]
January 9th Biotech Update
The sector has recovered a little but I would not say that it is anywhere near a really great place. We have moved from the edge of disaster and are more clearly within the trading range that seems to have developed. As I noted before any trading or movement this week can very easily be […]
January 6th Biotech Update
We are now making our way out of holiday trading and into what I would say is the first real trading day of the new year. I still think the sector trading will be focused on the upcoming JPM meeting next week and so whatever happens this week can change dramatically next. The key is […]
Mailing List
Introduction
Overview
Founded in 2011, Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.
The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate.
Subscribe to Chimera Research Group and proceed with confidence.
